))
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
Manage episode 414417312 series 3381434
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
CME credits: 0.25
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.=
…
continue reading
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/duchenne-muscular-dystrophy-differentiating-advances-in-treatment/16654/
There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.=
598 jaksoa
Jaa
